Hetherington J W, Siddall J K, Cooper E H
Unit for Cancer Research, University of Leeds, UK.
Eur Urol. 1988;14(1):1-5. doi: 10.1159/000472885.
Changes in the serial measurements of serum prostatic acid phosphatase (PAP), and prostatic specific antigen (PSA) have been compared against changes in serial bone scans in 120 patients with prostatic cancer. Of 54 patients who presented with negative bone scans 10 developed skeletal metastases, the PAP and PSA levels were rising in 5 and 9 of these patients, respectively. Local progression occurred in a further 9 patients in whom PAP was rising in 8 and PSA in all 9. In the 66 patients with previously documented skeletal metastases bone scan evidence of progression was seen in 36. At the time of the first evidence of progression PAP was rising in 20 (55%) and PSA was rising in 26 (72%). In 4 patients neither marker was raised at the time of first evidence of progression. We discuss the value of 'routine' serial bone scintigraphy in monitoring patients with prostatic cancer.
对120例前列腺癌患者血清前列腺酸性磷酸酶（PAP）和前列腺特异性抗原（PSA）的系列测量值变化与系列骨扫描变化进行了比较。54例骨扫描阴性的患者中，10例发生了骨转移，其中5例和9例患者的PAP和PSA水平分别升高。另外9例患者出现局部进展，其中8例患者的PAP升高，9例患者的PSA均升高。在66例先前有骨转移记录的患者中，36例骨扫描显示有进展迹象。在首次出现进展迹象时，20例（55%）患者的PAP升高，26例（72%）患者的PSA升高。4例患者在首次出现进展迹象时两种标志物均未升高。我们讨论了“常规”系列骨闪烁显像在监测前列腺癌患者中的价值。
